Clinical Trial Update: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lenalidomide plus rituximab in previously untreated mantle cell lymphoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-07